Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lilly Acquires Diabetes Candidates In Deal With Transition Therapeutics

This article was originally published in The Pink Sheet Daily

Executive Summary

After ending its efforts to develop inhaled insulin, Lilly rebuilds in-house pipeline of diabetes candidates.

You may also be interested in...

With Capital Scarce, Charities Emerge As A Stronger Force On Start-Up Scene

Disease charities are traditionally big funders of basic research. But those foundations are increasingly spawning specialized funds aimed at helping start-ups drive their candidates into later stages of development, where they might represent more attractive investment opportunities for pharmaceutical partners.

With Capital Scarce, Charities Emerge as a Stronger Force on Start-Up Scene

Disease-oriented foundations and cash-strapped biotechs are increasingly seeking common ground: as more becomes known about the mechanisms by which a given disease operates, foundation boards are finding more opportunities to fund promising start-ups and established biotechs.

Lilly Drops Inhaled-Insulin Program With Alkermes

Third casualty in the space leaves one late-stage player standing.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts